Introduction
The inward sodium current (I Na ) is responsible for the initial fast upstroke of the cardiac action potential (AP), determines excitability of myocardial cells and ensures proper conduction of the electrical impulse within the heart. The initial large inward I Na (peak I Na ) is for the most part rapidly inactivated, but a small fraction of the current (designated the late sodium current, I NaL ) may persist throughout the duration of the AP plateau phase. During normal conditions, I NaL has a very small amplitude (<1% of peak I Na ), 1 and may contribute to the AP plateau and (transmural) dispersion in AP duration (APD). 2 However, I NaL is enhanced during several congenital and acquired conditions associated with increased risk for lethal ventricular arrhythmias, including Long QT syndrome type 3 (LQT3), myocardial ischaemia and heart failure. 3 A continuous influx of sodium ions through increased I NaL not only prolongs APD, but may also lead to increased sodium concentrations and consequent calcium dysregulation within the cardiomyocyte. 4 Thus, enhanced I NaL has unfavourable consequences, making it an important potential therapeutic target for congenital and acquired conditions associated with increased I NaL . Currently, LQT3 patients at high risk for sudden arrhythmic death are treated with an implantable converter defibrillator (ICD), often in combination with b-blockers. 5 ICD firing however has a significant impact on quality of life, and may be associated with serious complications. 5, 6 Pharmacological inhibition of I NaL has been proposed as a potential therapeutic alternative in these patients. 7, 8 Currently available I NaL inhibitors, however, appear less suitable due to their potential blocking effect on the delayed rectifier potassium current I Kr , thereby prolonging APD. 1 Furthermore, they may also block peak I Na to some extent, potentially predisposing to cardiac conduction slowing and re-entrant tachycardias during specific conditions associated with reduced sodium channel function. 1, 7 Recently, the more selective, potent I NaL inhibitor GS-458967 (GS967; 6-(4-(trifluoromethoxy)phenyl)-3-(tri-fluoromethyl)- [1, 2, 4] triazolo [4,3-a] pyridine) was developed, showing beneficial effects on experimentally induced arrhythmias with minimal impact on other ion currents. 9, 10 However, the biophysical effects and potential antiarrhythmic actions have so far only been studied in the setting of chemically enhanced I NaL or using heterologous expression systems. [9] [10] [11] Here,
we determined the effects of GS967 in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) from a SCN5A-1795insD þ/-mutation carrier, and in knock-in mice harbouring the homologous mutation Scn5a-1798insD þ/-. 12, 13 This mutation is associated with both loss (reduced peak I Na ) and gain (increased I NaL ) of sodium channel function, 12, 13 allowing assessment of the effects of GS967 on ventricular repolarization and depolarization in the setting of compromised peak I Na .
Methods
2.1 Scn5a-1798insD þ/À mice Scn5a-1798insD þ/-mice on the 129P2 background were generated, maintained and genotyped as described previously. 12 For all experiments, heterozygous Scn5a-1798insD þ/-mice and wild type (WT) littermates (males and females) aged 3-5 months were used. Animal studies were performed in accordance with governmental and institutional guidelines.
Isolation of left ventricular cardiomyocytes
Mice were anesthetized by CO 2 /O 2 and sacrificed by cervical dislocation, after which the heart was excised, cannulated, mounted on a Langendorff set-up, and perfused at 37 C for 8 min with normal Tyrode's solution containing (in mmol/L): 140 NaCl, 5. 
SCN5A-1795insD þ/À and control hiPSC lines
The human induced pluripotent stem cell (hiPSC) control line (WT-D2-1-275) was previously generated and characterized at the University Medical Center of the Georg August University of Gottingen (Germany).
14 The hiPSC line carrying the SCN5A-1795insD þ/-mutation (LUMC0005iSCN03) was generated at the Leiden University Medical Center (The Netherlands). 13 Human skin biopsies were obtained after individual permission using standard informed consent procedures and approval of the local medical ethics committees. The study was performed conform the declaration of Helsinki.
Differentiation of hiPSC to cardiomyocytes
All hiPSC lines were expanded as adherent cultures in feeder-free conditions on matrigel-coated dishes in presence of chemically defined medium (E8 Essential Medium, Life Technologies). Differentiation of hiPSC to cardiomyocytes (CMs) was performed by following the previously reported protocol. 15 Details of the differentiation and cardiomyocytes-enrichment procedure were also previously described in . Hence, NaCl was replaced by CsCl (in mouse CMs:7 mmol/L NaCl and 133 mmol/L CsCl; in hiPSC-CMs: 20 mmol/L NaCl and 120 mmol/L CsCl). I NaL was measured at 36 C, as TTX-(30 lmol/L) and GS967-(300 nmol/L) sensitive current, using a descending ramp protocol at a cycle length of 5 s. Peak I Na was measured at room temperature from a holding potential of -120 mV following steps of 5 mV from -130 to þ30 mV for both mouse CMs and hiPSC-CMs, with a cycle length of 5 s. I Na was defined as the difference between peak and steady state current (at 500 ms). Current densities were calculated by dividing current amplitude by C m . Potentials were not corrected for the estimated change in liquid junction potential. Voltage dependence of activation and inactivation curves were fitted with Boltzmann function (
), where V 1/2 is the half -maximal voltage of (in)activation and k, the slope factor. Recovery from inactivation was assessed using a double pulse protocol. Data were normalized to the values of the current obtained during the first pulse (P1) and fitted with a bi-exponential func-
where A f and A s are the amplitudes of the fast and the slow components of recovery from inactivation, and s f and s s represent their respective recovery time constants. GS967 (provided by Gilead Sciences) was solubilized in DMSO as a stock solution of 10 mmol/L; the final DMSO concentration was <0.001% in both the GS967 and control bath solution.
Action potential measurements
In single mouse cardiomyocytes, APs were measured at 36 C using normal Tyrode's solution. Pipettes were filled with (in mmol/L): 125 Kgluconate, 20 KCl, 5 NaCl, 0.22 amphotericin-B, 10 HEPES, pH 7.2 (KOH). APs were elicited at 2 Hz by 2-ms, %1.2Â threshold current pulses through the patch pipette. In single hiPSC-CMs, APs were measured with similar conditions as for mouse cardiomyocytes, with exception that the amount of amphotericin was doubled. Typically, hiPSC-CMs have a small or even complete lack of the inward rectifying potassium current (I K1 ) . 16 Consequently, hiPSC-CMs have a depolarized resting membrane potential (RMP) and are frequently spontaneously active. 18 To overcome these conditions, which limit the functional availability of I Na , we injected an in silico I K1 with kinetics of Kir2.1 channels through dynamic clamp, 18 as previously described and validated in. 16 Consequently, cells became quiescent with a RMP of around -82 mV and APs were elicited at 0.5-2 Hz by 3 ms, %1.2-times the threshold current pulses through the patch pipette. We analysed RMP, AP amplitude (APA), maximal AP upstroke velocity (V max ) and APD at 20, 50, and 90% repolarization (APD 20 , APD 50 , and APD 90 , respectively). Data from 10 consecutive APs were averaged and potentials were corrected for the calculated liquid junction potential (15 mV). The fast pacing protocol used to count and quantify delayed after depolarizations (DADs) and triggered action potentials (TAPs) consisted in applying 20 pulse at a frequency of 5 Hz followed by a 10 second pause before, during and after application of GS967 (300 nmol/L). The results were normalized per trace using 5 consecutive traces.
Epicardial mapping in isolated hearts
Mice were anesthetized by CO 2 /O 2 and sacrificed by cervical dislocation, after which the heart was excised, cannulated, mounted on a Langendorff inter-electrode spacing 300 lm) was placed on the epicardium of the left ventricle (LV), and local extracellular electrograms were recorded during ventricular pacing from the central two electrodes of the grid (2 ms pulse duration, twice diastolic threshold) at a basic cycle length (BCL) of Figure 2 GS967 alters I Na inactivation properties in murine cardiomyocytes without affecting peak I Na density. Representative example of peak I Na current traces recorded in WT (A) and in Scn5a-1798insD þ/-(C) cardiomyocytes during a voltage step protocol before and after application of GS967
(300 nmol/L). Sodium current-voltage relationship in WT (B, n = 6 cardiomyocytes from 4 mice) and Scn5a-1798insD þ/-(D, n = 5 from 3 mice) cardiomyocytes before and after GS967 (300 nmol/L). (E,G) Voltage dependence of activation and inactivation of WT (E, n = 6 from 4 mice) and Scn5a-1798insD
(D, n = 5 from 3 mice) cardiomyocytes before and after application of GS967 (300 nmol/L). Time course of recovery from inactivation for WT (F, n = 7 from 6 mice) and Scn5a-1798insD þ/-(H, n = 5 from 3 mice) cardiomyocytes before and after application of GS967 (300 nmol/L 120 ms. Data were acquired using a custom-built data acquisition system. The effective refractory period (ERP) was determined by a train of 16 stimuli at BCL, followed by a single stimulus with progressively shortened coupling interval until the ventricles failed to be activated. The point of local activation was defined as the maximum negative slope (-dV/dt) of the electrogram. Local activation times, measured between the stimulus artefact and the -dV/dt, were used to construct ventricular activation maps. To calculate conduction velocity (CV) in longitudinal and transversal directions, the difference in activation time was determined between at least three consecutive electrode terminals, separated by a known distance and located parallel (longitudinal) or perpendicular (transversal) to the direction of propagation. The direction of propagation was determined using isochronal maps. Three parallel values of CV in each of the two directions were acquired and averaged.
Statistical analysis
Values are shown as mean ± S.E.M. Baseline, GS967 and washout measurements were performed in the same cardiomyocyte. Paired Student's t-test, Wilcoxon Signed-Rank test and one-or two-way repeated measures ANOVA followed by Holm-Sidak test for post hoc analysis were used when appropriate. In dose-response measurements, not all concentrations could be measured in every cell; systematic differences between cells were therefore first removed using factor-correction. 19 The remaining data were then considered independent measurements and effects of different concentrations of GS967 were subsequently compared with One-way ANOVA with Student-Newman-Keuls for multiple comparison of groups (SPSS, version 23). The level of statistical significance was set to P < 0.05. Average values for APA, RMP, V max , and APD at 20%, 50% and 90% repolarization (APD 20 , APD 50 , APD 90 ) at baseline and after GS967 (300 nmol/L) in WT (n = 18 cardiomyocytes from 14 mice) and Scn5a-1798insD þ/-cardiomyocytes (n = 14 from 10 mice). *P < 0.05,**P < 0.01, # P < 0.001; paired Student's t-test. (E): Typical examples of DADs (red arrows) and TAPs recorded after a fast pacing stimulation protocol (20 pulses at 5-Hz followed by a 10s pause) in Scn5a-1798insD þ/-cardiomyocytes before, during and after GS967 (300 nmol/L). Each picture (baseline, GS967, washout) is a superposition of 4 consecutive traces. (F) Average DADs amplitude and number of TAPs observed during each condition (n = 8 cardiomyocytes from 6 mice). Average numbers were calculated using five consecutive traces. *P < 0.05, One-way repeated measures ANOVA followed by Holm-Sidak test for post hoc analysis. 
Results

GS967 reduces I NaL in
The effect of GS967 (300 nmol/L) on TTX-sensitive I NaL was determined in LV cardiomyocytes isolated from adult WT and Scn5a-1798insD þ/-mice using a descending ramp after a 200-ms prepulse to 40 mV. The advantage of such a ramp protocol is that it, in contrast to a single step protocol, allows measurements of I NaL across a dynamic voltage range simulating a plateau and repolarization phase largely comparable to an AP. In WT cardiomyocytes, a small I NaL (-0.62 ± 0.08 pA/pF) was observed which was largely inhibited ($72%) by GS967 ( Figure 1A and B) .
As expected, Scn5a-1798insD þ/-cardiomyocytes displayed a more pronounced I NaL (-1.12 ± 0.09 pA/pF), 49% of which was inhibited by GS967, thereby normalizing I NaL magnitude to WT levels ( Figure 1C and D) .
3.2 GS967 does not affect peak I Na amplitude but alters I Na kinetics in mouse cardiomyocytes GS967 had no effect on maximal peak I Na density in either WT or Scn5a-1798insD þ/- (Figure 2A-D) cardiomyocytes. However, the compound caused a significant shift of the V 1/2 of inactivation towards more negative potentials in both WT and Scn5a-1798insD þ/-cardiomyocytes ( Figure 2E and G). Supplementary material online, Table S1 summarizes all V 1/2 and k values. Moreover, GS967 significantly impaired recovery from inactivation by increasing the time constants of both the slow and fast components in WT and Scn5a-1798insD þ/-cells (Figure 2F and H; see Supplementary material online, Table S1 ).
3.3 GS967 shortens APs and has antiarrhythmic effects in mouse Scn5a-1798insD þ/À cardiomyocytes Figure 3A and C shows typical APs and maximal upstroke velocities (V max ) of WT and Scn5a-1798insD þ/-cardiomyocytes before and after application of GS967 (300 nmol/L); Figure 3B and C summarizes average AP characteristics. In both WT and Scn5a-1798insD þ/-cells, GS967 significantly decreased APD, normalizing APD in Scn5a-1798insD þ/-to values similar to WT. A small but significant decrease in V max was induced by GS967 in both WT and Scn5a-1798insD þ/-cardiomyocytes, in addition to a slight yet significant hyperpolarization of RMP in both groups (see Supplementary material online, Table S2 and Figure S1 ). Moreover, APA was significantly reduced in Scn5a-1798insD þ/-cardiomyocytes. The effects of GS967 on APD and V max were dose-dependent (see Supplementary material online, Figure S2 and Table S3 ).
Following fast-pacing, Scn5a-1798insD þ/-cardiomyocytes displayed frequent DADs and TAPs under baseline conditions ( Figure 3E ). The incidence of DADs per trace in Scn5a-1798insD þ/-cardiomyocytes was not significantly different before (1.34 ± 0.28) and after (1.33 ± 0.31) administration of GS967 (300 nmol/L). However, GS967 significantly reduced DADs amplitude and thereby the frequency of TAPs ( Figure 3F) . Thus, 
GS967 decreased the pro-arrhythmic events in Scn5a-1798insD
þ/-cardiomyocytes.
GS967 does not affect ventricular conduction in isolated mouse hearts
We next tested the effects of GS967 (300 nmol/L) on cardiac conduction using epicardial mapping in isolated hearts. Perfusion with GS967
increased ERP, most notably and significantly in Scn5a-1798insD
hearts (see Supplementary material online, Table S4 ). GS967 did not affect total LV activation time, transversal or longitudinal conduction velocities in either WT or Scn5a-1798insD þ/-hearts ( Figure 4A and B) . In two Scn5a-1798insD þ/-hearts (but no WT hearts), ventricular tachycardia was induced at baseline after application of one short-coupled stimulus, which was prevented by GS967 ( Figure 4C) . Thus, GS967 did not impair conduction on the whole heart level, while it showed potential (although anecdotal) anti-arrhythmic effects.
3.5 GS967 inhibits I NaL , alters I Na kinetics and shortens APs in SCN5A-1795insD
hiPSC-CMs
To extend our findings, we also assessed the effects of GS967 in hiPSC-CMs from a SCN5A-1795insD þ/-mutation carrier. Although I NaL was absent from control hiPSC-CMs, a clear TTX-sensitive I NaL was observed in SCN5A-1795insD þ/-hiPSC-CMs upon application of the descending ramp protocol, which was significantly reduced by GS967 (300 nmol/L) ( Figure 5A and B) . Similar to mouse cardiomyocytes, GS967 had no effect on maximal peak I Na in either control and SCN5A-1795insD þ/-hiPSC-CMs ( Figure 5C-F) , but caused a significant negative shift in voltage-dependence of inactivation in both groups; additionally, GS967 also shifted the voltage-dependence of activation towards more negative potentials (Figure 6A and C; see Supplementary material online, Table S5 ). Furthermore, GS967 significantly slowed recovery from inactivation in control and SCN5A-1795insD þ/-hiPSC-CMs (Figure 6B and D; see Supplementary material online, Table S5 ). AP measurements, performed in the presence of an in silico injected inward rectifier potassium current (I K1 ) using the dynamic clamp technique, 16 demonstrated that GS967 induced a significant reduction in APA and V max in both control and SCN5A- Table S6 and, Figure S3 ), which was more pronounced at higher stimulation frequencies (see Supplementary material online, Figure S4 ). Furthermore, GS967 caused a significant decrease in APD in SCN5A-1795insD þ/-hiPSC-CMs ( Figure 7C and D, without affecting APD in control hiPSC-CMs (Figure 7A and B; see Supplementary material online, Table S6 and Figure S3) . Thus, the effects of GS967 in the human cardiomyocyte environment were largely similar to those in mice, including reduction of I NaL and a marked shortening of APD.
Discussion
SCN5A mutations underlying LQT3 are typically associated with enhanced I NaL and AP prolongation predisposing to life-threatening ventricular arrhythmias and sudden cardiac death. Pharmacological inhibition of I NaL has been proposed as a potential therapeutic strategy in conditions with enhanced I NaL , including LQT3. Indeed, the I NaL inhibitor ranolazine decreased APD and incidence of arrhythmias in experimental models of LQT3, 8 and shortened QTc-intervals in a small series of five LQT3 patients carrying the SCN5A-deltaKPQ mutation. 20 However, when considering the clinical application of I NaL inhibitors, it is important to minimize potential detrimental effects on peak I Na and other ion currents. Ranolazine may cause modest AP prolongation due to its I Kr blocking action; moreover, its peak I Na inhibiting effects are more pronounced at higher frequencies and at more depolarized membrane potentials (e.g. during ischaemia). 1 Recently, a novel inhibitor of I NaL , GS967 was identified, which blocks I NaL $100-fold more potent than peak I Na in rabbit ventricular myocytes, with minimal or no apparent effects on other ion currents. 9 Although the effects of GS967 on peak I Na and V max in rabbit myocytes were voltagedependent, they were frequency-dependent to a much lesser extent. 9 Furthermore, GS967 displayed anti-arrhythmic effects in the setting of ATX-II-induced I NaL in rabbit isolated hearts and cardiomyocytes, canine Purkinje fibers and pulmonary vein and superior vena cava sleeve preparations. 9, 10 Importantly, in contrast to flecainide, which increases VT/VF occurrence during ischaemia, GS967 reduced both. 9 We here employed murine cardiomyocytes and hiPSC-CMs carrying the Scn5a-1798insD
þ/-mutation associated with an overlap syndrome of both loss (reduced peak I Na ) and gain (enhanced I NaL ) of sodium channel function. 12, 13 Our study is timely given the ongoing pivotal clinical trial (NCT02300558) investigating the electrophysiological effects of another selective I NaL inhibitior (GS-6615; eleclazine) in patients with LQT3 syndrome. We demonstrate that GS967 decreases I NaL and APD, without affecting cardiac conduction. Our findings furthermore provide evidence for an anti-arrhythmic effect of GS967 in the setting of an LQT3-causing mutation. Enhanced I NaL may have pro-arrhythmic consequences due to two separate mechanisms.
The inward, depolarizing current reduces repolarization rate, resulting in prolonged APD and increased susceptibility to early after depolarizations (EADs) at slow pacing rates. 12 A sustained influx of sodium ions through increased I NaL may furthermore cause elevated intracellular sodium levels, ultimately leading to increased intracellular calcium concentration within the cardiomyocyte secondary to reverse-mode activity of the sodium-calcium exchanger, thereby facilitating the occurrence of DADs and triggered activity. 4, 21 In the present study, we did not observe EADs, but murine Scn5a-1798insD þ/-cardiomyocytes displayed frequent DADs and triggered activity. GS967 reduced the number of TAPs, likely due to reduction in amplitude of DADs, consistent with its proposed anti-arrhythmic actions. 9 Although GS967 did not reduce peak I Na , it caused a modest yet significant decrease in AP upstroke velocity in murine cardiomyocytes and hiPSC-CMs. This apparent discrepancy is likely due to the GS967-induced negative shift in inactivation, which in combination with the slowed recovery from inactivation (similar to previously observed in HEK293 cells 11 ), may reduce sodium channel availability. Nevertheless, the observed reduction in V max by GS967 did not affect ventricular conduction in WT or Scn5a-1798insD þ/-mouse hearts, a finding in keeping with previous observations that up to 50% reduction in I Na may not affect cardiac conduction due to inherent conduction reserve. 22 Hence, anti-arrhythmic effects of GS967 through restoration of APD is not expected to be compromised by its limited inhibition of peak I Na . Moreover, as previously described in Ref. 11 the observed impairment of recovery from inactivation by GS967 may have anti-arrhythmic effects through use-dependent block and post-repolarization refractoriness, thereby diminishing excitability of premature beats. Both the observed frequency-dependency of sodium channel availability (V max ) in hiPSC-CMs and the ERP prolongation in isolated mouse hearts are in line with this interpretation. The highly concordant results obtained in both mouse and human models support the use of hiPSC-CMs as a valuable tool for assessment of novel pharmacological approaches in inherited sodium channelopathies. Nevertheless, our findings also underline the importance of in vivo and/or ex vivo experiments in order to avoid misinterpretation of the impact of a compound based solely on its effect at a cellular level.
In conclusion, selective I NaL inhibition by GS967 suppressed the detrimental gain-of-function features of the SCN5A-1795insD þ/-overlap syndrome mutation in both human and murine models. Importantly, these beneficial actions of GS967 occurred in the absence of deleterious effects on cardiac conduction, despite the decreased peak I Na associated with the mutation. Thus, selective I NaL inhibition constitutes a promising pharmacological treatment of cardiac channelopathies associated with enhanced I NaL , even in conditions where peak I Na is decreased.
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